Cargando…

Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis

INTRODUCTION: Nonclear cell (NCC) metastatic renal cell carcinoma (mRCC) is a biologically heterogeneous entity. We report the outcomes of NCC mRCC treated with first-line vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin (mTOR) inhibitors at our institute. This i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwala, Vivek, Ramaswamy, Anant, Joshi, Amit, Patil, Vijay Maruti, Noronha, Vanita, Menon, Santosh, Popat, B. Palak, Sable, Nilesh, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	ORIGINAL ARTICLE: Genitourinary Cancers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190394/ https://www.ncbi.nlm.nih.gov/pubmed/30430089 http://dx.doi.org/10.4103/sajc.sajc_22_18

Ejemplares similares

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
por: Joshi, Amit, et al.
Publicado: (2020)

Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center
por: Ramaswamy, Anant, et al.
Publicado: (2017)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
por: Patil, Vijay M., et al.
Publicado: (2016)

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal
por: Noronha, Vanita, et al.
Publicado: (2015)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Management of testicular tumours in patients with undescended testes— a challenging but rewarding task: experience from a tertiary care cancer centre in India
por: Tongaonkar, Arnav, et al.
Publicado: (2023)

Nephron-Sparing Robotic Radiosurgical Therapy for Primary Renal Cell Carcinoma: Single-Institution Experience and Review of the Literature
por: Peddada, Anuj V., et al.
Publicado: (2019)

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors
por: Funt, Samuel A., et al.
Publicado: (2021)

Primary malignant mediastinal germ cell tumors: A single institutional experience
por: Mishra, Subhasis, et al.
Publicado: (2020)

ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
por: Patil, Anand, et al.
Publicado: (2021)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
por: Patil, Vijay, et al.
Publicado: (2021)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
por: Patil, Vijay, et al.
Publicado: (2018)

Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study
por: Dahn, Hannah M., et al.
Publicado: (2019)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities
por: Mahmoud, Ahmed M, et al.
Publicado: (2023)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)

Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!
por: Patil, Vijay Maruti, et al.
Publicado: (2020)

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
por: Alhalabi, Omar, et al.
Publicado: (2023)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Utilization of Stereotactic Ablative Body Radiation Therapy for Intact Renal Cell Carcinoma: Trends in Treatment and Predictors of Outcome
por: Wegner, Rodney E., et al.
Publicado: (2019)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
por: Motzer, Robert, et al.
Publicado: (2023)

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
por: Park, Hyo Jung, et al.
Publicado: (2022)

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
por: McGregor, Bradley, et al.
Publicado: (2023)

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
por: Bergerot, Cristiane, et al.
Publicado: (2023)

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study
por: Kraus, Ryan Douglas, et al.
Publicado: (2018)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Second-line therapy in testicular germ cell tumours: results from a tertiary cancer care centre in India
por: Joshi, Amit, et al.
Publicado: (2022)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_36gp0n25r5rtncmtkro0g7nfr1